PD-1 PD-L1单抗在复发 转移性鼻咽癌中的研究进展

Research progress of PD-1/PD-L1 monoclonal antibodies in recurrent/metastatic nasopharyngeal carcinoma

鼻咽癌患者经放疗及同步辅助化疗后,临床转归有所改善,但肿瘤复发及远处转移仍为一项难题。近些年,免疫检查点抑制剂的发现为肿瘤的免疫治疗提供了新的选择。其中,程序性细胞死亡受体1(programmed cell death protein-1,PD-1)/程序性死亡受体配体1(programmed cell death 1-ligand,PD-L1)单抗受到广泛关注且已应用于临床治疗。本文就帕博利珠单抗、纳武利尤单抗、卡瑞利珠单抗和特瑞普利单抗等PD-1/PD-L1单抗在复发/转移性鼻咽癌中的研究进展进行综述。

Clinical outcomes of patients with nasopharyngeal carcinoma have improved after radiotherapy and concurrent adjuvant chemotherapy.However,tumor recurrence and distant metastasis remain a problem.In recent years,immune checkpoint inhibitors have provided new options for tumor immunotherapy.Among immune checkpoint inhibitors,programmed cell death protein-1(PD-1)/programmed cell death protein-ligand 1(PD-L1)monoclonal antibodies have received widespread attention and have been used in clinical treatments.This article reviews the research progress of pembrolizumab,nivolizumab,carrelizumab,teriprizumab,and other PD-1/PD-L1 monoclonal antibodies in recurrent/metastatic nasopharyngeal carcinoma.